{"id":"W3012535443","doi":"10.1038/s41416-020-0774-1","title":"Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours","year":2020,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Astellas Pharma; Imperial Experimental Cancer Medicine Centre; Ono Pharmaceutical; Eisai; National Institute for Health and Care Research; Advanced Accelerator Applications; Daiichi Sankyo Europe; Bayer HealthCare; Sanofi; Exelixis; Astex Pharmaceuticals; Taiho Pharmaceutical; Boehringer Ingelheim; Yuhan; Gilead Sciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pharmacokinetics; Medicine; Pharmacodynamics; Internal medicine; Toxicity; Adverse effect; Dosing; Oncology; Insulin-like growth factor; Pharmacology; Growth factor; Gastroenterology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001808706,0.000313686,0.001269884,0.0003258955,0.00009854534,0.00003789218,0.0002436959,0.0000896296,0.00005566477],"category_scores_gemma":[0.0002157419,0.0003001316,0.0001964251,0.0005953366,0.0001883028,0.0005658765,0.00006514989,0.0007115959,0.000001114042],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003557657,"about_ca_system_score_gemma":0.0002820881,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005688001,"about_ca_topic_score_gemma":0.0009916084,"domain_scores_codex":[0.9969786,0.00007987351,0.001347215,0.0003394006,0.0007697627,0.0004851129],"domain_scores_gemma":[0.9977933,0.00007064197,0.0008374795,0.00013506,0.0008700765,0.0002935105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002173773,0.0006352759,0.984222,0.0005325784,0.00033158,0.000884966,0.003107215,0.0002177612,0.004522366,0.00001713286,0.000314609,0.003040761],"study_design_scores_gemma":[0.01948571,0.002380532,0.9680312,0.003649062,0.0001495175,0.00005805956,0.0006762624,0.00001434287,0.004997144,0.00004736185,0.0001885074,0.0003222441],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900575,0.008597305,0.00001103514,0.0004077615,0.0002685572,0.0004724048,0.00005019383,0.00001766884,0.0001175468],"genre_scores_gemma":[0.9952155,0.00365359,0.0002446705,0.0005877294,0.0002041073,0.000009153327,0.00001506873,0.00006037412,0.000009769188],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01731194,"threshold_uncertainty_score":0.9999451,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02260560346040347,"score_gpt":0.3198738740015921,"score_spread":0.2972682705411887,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}